EDWARD PEARCE: Open Payments
NPI 1184085797 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,451 in 161 payments from 17 companies in 2025. Trend: 2023 $3,381 · 2024 $3,475 · 2025 $2,451
Food & beverage: $2,451
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 20 | $360 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 42 | $327 |
| Collegium Pharmaceutical, Inc. | 17 | $291 |
| Axsome Therapeutics, Inc. | 16 | $290 |
| Lundbeck LLC | 11 | $225 |
| Janssen Pharmaceuticals, Inc | 10 | $164 |
| Neurocrine BioSciences, Inc. | 8 | $156 |
| Teva Pharmaceuticals USA, Inc. | 11 | $144 |
| Vanda Pharmaceuticals Inc. | 4 | $107 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
Products named: ARISTADA, CAPLYTA, REXULTI, Jornay PM, Auvelity, INGREZZA, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across FL — which companies pay providers there.
